Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Conscience
Deal Size : $1.1 million
Deal Type : Funding
Conscience Announces Recipients of Inaugural Program for Drug Discovery
Details : The funding will be used for the pre-clinical development of an ALK2 inhibitor for the treatment of diffuse intrinsic pontine glioma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 27, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Conscience
Deal Size : $1.1 million
Deal Type : Funding